$CYTK
CYTOKINETICS INC

2018 Q1 Form 10-K Financial Statement

#000156459018004398 Filed on March 05, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017 Q3
Revenue $5.268M -$18.00K $6.180M
YoY Change 26.85% -100.05% -89.53%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.260M $10.26M $9.660M
YoY Change 14.04% 53.82% 33.8%
% of Gross Profit
Research & Development $22.14M $26.25M $24.95M
YoY Change 14.75% 39.78% 29.01%
% of Gross Profit
Depreciation & Amortization $673.0K $610.0K $450.0K
YoY Change 59.86% 177.27% 150.0%
% of Gross Profit
Operating Expenses $31.40M $36.51M $34.60M
YoY Change 14.58% 43.46% 30.29%
Operating Profit -$26.13M
YoY Change 12.39%
Interest Expense $863.0K -$3.960M -$3.930M
YoY Change 15.84% 647.17% -650.42%
% of Operating Profit
Other Income/Expense, Net $842.0K
YoY Change 93.12%
Pretax Income -$30.28M -$40.49M -$32.36M
YoY Change 17.06% -665.5% -196.99%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$30.28M -$40.48M -$32.36M
YoY Change 17.06% -665.66% -196.99%
Net Earnings / Revenue -574.81% -523.58%
Basic Earnings Per Share -$0.60
Diluted Earnings Per Share -$560.1K -$806.6K -$0.60
COMMON SHARES
Basic Shares Outstanding 54.01M 53.72M
Diluted Shares Outstanding 53.72M

Balance Sheet

Concept 2018 Q1 2017 Q4 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $251.5M $268.9M $307.6M
YoY Change 21.76% 72.09% 291.3%
Cash & Equivalents $115.0M $125.2M $116.3M
Short-Term Investments $136.4M $143.7M $191.2M
Other Short-Term Assets $2.300M $4.300M $4.400M
YoY Change -36.11% 95.45% 69.23%
Inventory
Prepaid Expenses
Receivables $18.60M $1.112M $10.00M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $272.3M $274.3M $322.0M
YoY Change 29.04% 72.91% 117.3%
LONG-TERM ASSETS
Property, Plant & Equipment $3.200M $3.568M $3.300M
YoY Change -8.26% -1.9% 61.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.000M $16.50M $600.0K
YoY Change -92.09% 114.29% -92.21%
Other Assets $400.0K $429.0K $400.0K
YoY Change 65.98% 114.5% 100.0%
Total Long-Term Assets $7.600M $20.52M $4.300M
YoY Change -86.02% 78.25% -56.94%
TOTAL ASSETS
Total Short-Term Assets $272.3M $274.3M $322.0M
Total Long-Term Assets $7.600M $20.52M $4.300M
Total Assets $279.9M $294.8M $326.3M
YoY Change 5.47% 73.27% 106.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.400M $5.253M $4.100M
YoY Change -21.1% 24.01% 513.77%
Accrued Expenses $15.50M $17.39M $18.50M
YoY Change -11.44% -3.63% 4.03%
Deferred Revenue $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $9.800M
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $38.55M $32.44M $42.40M
YoY Change 4.76% -2.45% 44.54%
LONG-TERM LIABILITIES
Long-Term Debt $31.95M $31.78M $20.50M
YoY Change 26.83% 16.05% -31.07%
Other Long-Term Liabilities $1.035M $1.097M $116.4M
YoY Change -99.04% 672.54% 636.71%
Total Long-Term Liabilities $32.99M $32.87M $136.9M
YoY Change 30.93% 19.44% 360.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $38.55M $32.44M $42.40M
Total Long-Term Liabilities $32.99M $32.87M $136.9M
Total Liabilities $180.3M $185.0M $179.3M
YoY Change 6.08% 144.08% 139.32%
SHAREHOLDERS EQUITY
Retained Earnings -$658.3M -$646.1M
YoY Change 20.98% 24.66%
Common Stock $757.5M $755.6M
YoY Change 18.44% 23.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $99.60M $109.8M $147.0M
YoY Change
Total Liabilities & Shareholders Equity $279.9M $294.8M $326.3M
YoY Change 5.48% 73.27% 106.3%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017 Q3
OPERATING ACTIVITIES
Net Income -$30.28M -$40.48M -$32.36M
YoY Change 17.06% -665.66% -196.99%
Depreciation, Depletion And Amortization $673.0K $610.0K $450.0K
YoY Change 59.86% 177.27% 150.0%
Cash From Operating Activities -$29.81M -$24.07M -$25.48M
YoY Change 42.34% -130.93% 110.23%
INVESTING ACTIVITIES
Capital Expenditures $261.0K -$780.0K -$450.0K
YoY Change -81.2% -9.3% 50.0%
Acquisitions
YoY Change
Other Investing Activities $20.40M $31.54M $40.11M
YoY Change -118.39% -176.7% 180.88%
Cash From Investing Activities $20.14M $30.76M $39.66M
YoY Change -117.93% -173.29% 183.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -520.0K 2.190M 1.440M
YoY Change -100.45% 208.45% 97.26%
NET CHANGE
Cash From Operating Activities -29.81M -24.07M -25.48M
Cash From Investing Activities 20.14M 30.76M 39.66M
Cash From Financing Activities -520.0K 2.190M 1.440M
Net Change In Cash -9.671M 8.880M 15.62M
YoY Change -44.77% -75.72% 505.43%
FREE CASH FLOW
Cash From Operating Activities -$29.81M -$24.07M -$25.48M
Capital Expenditures $261.0K -$780.0K -$450.0K
Free Cash Flow -$30.07M -$23.29M -$25.03M
YoY Change 34.66% -129.6% 111.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54008113
CY2017Q2 dei Entity Public Float
EntityPublicFloat
630800000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
125206000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66874000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
143685000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
89375000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1112000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24000
CY2017Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
16518000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9572000
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
294810000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
16453000
CY2017 cytk Proceeds From Sale Of Future Royalties Net Of Issuance Costs
ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts
90621000
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
135000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
503000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2360000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4292000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
274295000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
158633000
CY2016Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
7672000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-127584000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
92064000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5253000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4236000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3568000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3637000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
429000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
200000
CY2017Q4 us-gaap Assets
Assets
294810000
CY2016Q4 us-gaap Assets
Assets
170142000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1097000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
755526000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-646081000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17392000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
109842000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
170142000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18047000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8060000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
142000
CY2017Q4 us-gaap Liabilities
Liabilities
184968000
CY2016Q4 us-gaap Liabilities
Liabilities
75781000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2500000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
54000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
227000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
612474000
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
415000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
343000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
137000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32444000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-518291000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33258000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
94361000
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
31777000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
27381000
CY2017Q4 cytk Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
104650000
CY2016Q4 cytk Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
0
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
15000000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
15000000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-113396000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1167000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-127790000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2602000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
163000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
163000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53960832
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40646595
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53960832
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40646595
CY2017 cytk Research And Development Grant And Other Revenues Net
ResearchAndDevelopmentGrantAndOtherRevenuesNet
4569000
CY2016 cytk Research And Development Grant And Other Revenues Net
ResearchAndDevelopmentGrantAndOtherRevenuesNet
44236000
CY2015 cytk Research And Development Grant And Other Revenues Net
ResearchAndDevelopmentGrantAndOtherRevenuesNet
14740000
CY2017 us-gaap License And Services Revenue
LicenseAndServicesRevenue
8799000
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
62171000
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
13918000
CY2016 us-gaap Revenues
Revenues
106407000
CY2015 us-gaap Revenues
Revenues
28658000
CY2017 us-gaap Interest Expense
InterestExpense
3016000
CY2016 us-gaap Interest Expense
InterestExpense
2698000
CY2017 cytk Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
13980000
CY2016 cytk Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
0
CY2015 cytk Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
0
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
464000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-37501000
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.59
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.59
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49404000
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39943000
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38814000
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49404000
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42561000
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38814000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
427000
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
69000
CY2015 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
144000
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
282000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4567000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
153000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
68590000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
917000
CY2016 cytk Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
611000
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
288000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7146000
CY2017 cytk Stock Issued During Period Value Secondary Offering
StockIssuedDuringPeriodValueSecondaryOffering
82370000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-12000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1918000
CY2017 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
904000
CY2017 cytk Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
12071000
CY2017 cytk Stock Issued During Period Value Royalty Purchase Agreement
StockIssuedDuringPeriodValueRoyaltyPurchaseAgreement
7560000
CY2016 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
145158000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9028000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
206000
CY2017 cytk Stock Issued During Period Value Secondary Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueSecondaryOfferingNetOfIssuanceCosts
3400000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1920000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
741000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
589000
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
67000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
18000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
18000
CY2017 cytk Non Cash Interest Expense Related To Long Term Debt
NonCashInterestExpenseRelatedToLongTermDebt
635000
CY2016 cytk Non Cash Interest Expense Related To Long Term Debt
NonCashInterestExpenseRelatedToLongTermDebt
534000
CY2015 cytk Non Cash Interest Expense Related To Long Term Debt
NonCashInterestExpenseRelatedToLongTermDebt
3000
CY2017 cytk Non Cash Interest Expense Related To Sale Of Future Royalties
NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
14028000
CY2016 cytk Non Cash Interest Expense Related To Sale Of Future Royalties
NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
0
CY2015 cytk Non Cash Interest Expense Related To Sale Of Future Royalties
NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
0
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
9028000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
7146000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
4567000
CY2017 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
0
CY2016 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
0
CY2015 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
3000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1088000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-46634000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2161000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
707000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
396000
CY2017 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1457000
CY2016 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1698000
CY2015 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
755000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
766000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8945000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2995000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1513000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2202000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12742000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-101759000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
36982000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
4883000
CY2017 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
240413000
CY2015 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
115566000
CY2017 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
177462000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
94645000
CY2015 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
132190000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2877000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1596000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
562000
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
33000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-65828000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-52076000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
16063000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
112224000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8673000
CY2016 cytk Proceeds From Sale Of Future Royalties Net Of Issuance Costs
ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts
0
CY2015 cytk Proceeds From Sale Of Future Royalties Net Of Issuance Costs
ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts
0
CY2017 cytk Proceeds From Issuance Of Common Stock Related To Sale Of Future Royalties Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockRelatedToSaleOfFutureRoyaltiesNetOfIssuanceCosts
7560000
CY2016 cytk Proceeds From Issuance Of Common Stock Related To Sale Of Future Royalties Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockRelatedToSaleOfFutureRoyaltiesNetOfIssuanceCosts
0
CY2015 cytk Proceeds From Issuance Of Common Stock Related To Sale Of Future Royalties Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockRelatedToSaleOfFutureRoyaltiesNetOfIssuanceCosts
0
CY2017 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
1261000
CY2016 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
14996000
CY2015 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
14890000
CY2017 cytk Proceeds And Payments From Stock Based Award And Warrants Net Of Issuance Costs
ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts
-14253000
CY2016 cytk Proceeds And Payments From Stock Based Award And Warrants Net Of Issuance Costs
ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts
-1896000
CY2015 cytk Proceeds And Payments From Stock Based Award And Warrants Net Of Issuance Costs
ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts
-352000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
225919000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16892000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
23915000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
58332000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1798000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
44861000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65076000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20215000
CY2017 us-gaap Interest Paid
InterestPaid
2128000
CY2016 us-gaap Interest Paid
InterestPaid
1899000
CY2015 us-gaap Interest Paid
InterestPaid
94000
CY2017 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2016 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2015 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p></div>
CY2016Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
1888000
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments, long term debt and accounts receivable.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash, cash equivalents and investments are invested in deposits with three major financial institutions in the United States.&#160;Deposits in these banks may exceed the amount of insurance provided on such deposits. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s exposure to credit risk associated with non-payment is limited to its strategic partners Amgen Inc., (&#8220;Amgen&#8221;) and Astellas Pharma Inc., (&#8220;Astellas&#8221;) and any material non-payment from our partners would result in a material breach of the agreements underlying the strategic partnerships. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug candidates developed by the Company may require approvals or clearances from the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agencies prior to commercial sales. There can be no assurance that the Company&#8217;s drug candidates will receive any of the required approvals or clearances. If the Company was to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on the Company.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></div>
CY2017 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Prior Year&#8217;s Presentations</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Certain amounts in the prior year&#8217;s presentations have been reclassified to conform to the current presentation. These reclassifications had no effect on previously reported net income.</p></div>
CY2017Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
285400000
CY2016Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
163900000
CY2017 cytk Cash Requirements Term
CashRequirementsTerm
P12M
CY2017Q4 cytk Number Of Financial Institutions
NumberOfFinancialInstitutions
3
CY2018Q1 us-gaap Proceeds And Excess Tax Benefit From Sharebased Compensation
ProceedsAndExcessTaxBenefitFromSharebasedCompensation
700000
CY2017 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
CY2016 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2019000
CY2015 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
CY2017 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2016 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
409000
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2017 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0
CY2016 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
181000
CY2015 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0
CY2017 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
0
CY2016 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
9000
CY2015 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
0
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2016 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2618000
CY2015 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6534000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3688000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11249000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2017Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
31800000
CY2016Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
29900000
CY2017Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2017Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26194000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24755000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22626000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21118000
CY2017 us-gaap Depreciation
Depreciation
1900000
CY2016 us-gaap Depreciation
Depreciation
700000
CY2015 us-gaap Depreciation
Depreciation
600000
CY2017Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
8370000
CY2016Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
10092000
CY2017Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4054000
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3800000
CY2017Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
2207000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1426000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
897000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1335000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
698000
CY2017Q4 cytk Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
0
CY2016Q4 cytk Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
672000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
500000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
500000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
CY2017 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
11000000
CY2017 cytk Percentage Of Shared Costs
PercentageOfSharedCosts
0.75
CY2015Q3 cytk Research Development Grant
ResearchDevelopmentGrant
1500000
CY2015Q3 cytk Potential Milestone Payments Upon Achievement Of Milestone
PotentialMilestonePaymentsUponAchievementOfMilestone
500000
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
32000000
CY2016Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
325000
CY2016Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
472000
CY2017Q4 cytk Debt Instrument Accretion Of Final Exit Fee
DebtInstrumentAccretionOfFinalExitFee
102000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9028000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.51
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.00
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.00
CY2017 cytk Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited
EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited
-0.10
CY2016Q4 cytk Debt Instrument Accretion Of Final Exit Fee
DebtInstrumentAccretionOfFinalExitFee
353000
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
31777000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4250000
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
29881000
CY2017Q1 cytk Effective Annual Interest Rate In Calculating Liability Related To Sale Of Future Royalties
EffectiveAnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties
0.17
CY2017 cytk Royalty Purchase Agreement Arrangements Consideration
RoyaltyPurchaseAgreementArrangementsConsideration
100000000
CY2017 cytk Transaction Costs Incurred In Connection With Royalty Monetization And Rpi Common Stock
TransactionCostsIncurredInConnectionWithRoyaltyMonetizationAndRpiCommonStock
1800000
CY2017 cytk Non Cancelable Lease Expiration Year
NonCancelableLeaseExpirationYear
2021
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3627000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3448000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3297000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3789000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4682000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4846000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2465000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
15782000
CY2016 us-gaap Litigation Settlement Amount Awarded From Other Party
LitigationSettlementAmountAwardedFromOtherParty
4500000
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
100106
CY2017Q4 cytk Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
6.74
CY2017 cytk Warrant Expiration Period
WarrantExpirationPeriod
2017-06
CY2017 cytk Number Of Issued Shares Of Common Stock Related To Cashless Exercise Of Warrants
NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants
3450122
CY2016 cytk Number Of Issued Shares Of Common Stock Related To Cashless Exercise Of Warrants
NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants
834998
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5192813
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1310674
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
281865
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5957458
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4019836
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5866326
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.27
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.74
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.26
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
24.45
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.19
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.01
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.18
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M9D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M24D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y6M25D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4287000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3300000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7146000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4567000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 cytk Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Due To Pre Tax Income Loss
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateDueToPreTaxIncomeLoss
-0.34
CY2016 cytk Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Due To Pre Tax Income Loss
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateDueToPreTaxIncomeLoss
0.34
CY2015 cytk Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Due To Pre Tax Income Loss
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateDueToPreTaxIncomeLoss
-0.34
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.00
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.02
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.00
CY2017 cytk Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
0.00
CY2016 cytk Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
-0.07
CY2015 cytk Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
0.00
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.08
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.32
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.07
CY2016 cytk Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited
EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited
-0.15
CY2015 cytk Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited
EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited
0.37
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
218811000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.00
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.07
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.02
CY2017 cytk Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.00
CY2016 cytk Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.09
CY2015 cytk Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.02
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.01
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.02
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-127235000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
16453000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-37501000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-555000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-127790000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16453000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37501000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
98630000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
146961000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
153251000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
64185000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
46998000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
38742000
CY2017Q4 cytk Deferred Tax Assets Liability Related To Sale Of Future Royalties
DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties
24593000
CY2016Q4 cytk Deferred Tax Assets Liability Related To Sale Of Future Royalties
DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties
0
CY2015Q4 cytk Deferred Tax Assets Liability Related To Sale Of Future Royalties
DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties
0
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
10524000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
10258000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
12899000
CY2017Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
6432000
CY2016Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
11675000
CY2015Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
13150000
CY2017Q4 cytk Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
546000
CY2016Q4 cytk Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
766000
CY2015Q4 cytk Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
769000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
204910000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
216658000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
204910000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
216658000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
218811000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017 cytk Research And Development Federal Tax Credit Carryforwards Expiration Date Year
ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear
2021
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-11700
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-2100000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13900000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7565000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6715000
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
5000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1800000
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.77
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
845000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9365000
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
8100000
CY2016Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
6300000
CY2015Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
5500000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017Q4 cytk Tax Cuts And Jobs Act Of2017 Change In Tax Rate Estimated Reduction In Deferred Tax Assets
TaxCutsAndJobsActOf2017ChangeInTaxRateEstimatedReductionInDeferredTaxAssets
68300000
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
4153000
CY2017Q2 us-gaap Sales Revenue Net
SalesRevenueNet
3053000
CY2017Q3 us-gaap Sales Revenue Net
SalesRevenueNet
6180000
CY2017Q4 us-gaap Sales Revenue Net
SalesRevenueNet
-18000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-25867000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-29081000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-32357000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-40484000
CY2017Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.62
CY2017Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.60
CY2017Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.60
CY2017Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.75
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
8421000
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
5802000
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
59047000
CY2016Q4 us-gaap Sales Revenue Net
SalesRevenueNet
33138000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-12455000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-11611000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
33362000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
7157000
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29

Files In Submission

Name View Source Status
0001564590-18-004398-index-headers.html Edgar Link pending
0001564590-18-004398-index.html Edgar Link pending
0001564590-18-004398.txt Edgar Link pending
0001564590-18-004398-xbrl.zip Edgar Link pending
cytk-10k_20171231.htm Edgar Link pending
cytk-20171231.xml Edgar Link completed
cytk-20171231.xsd Edgar Link pending
cytk-20171231_cal.xml Edgar Link unprocessable
cytk-20171231_def.xml Edgar Link unprocessable
cytk-20171231_lab.xml Edgar Link unprocessable
cytk-20171231_pre.xml Edgar Link unprocessable
cytk-ex1045_682.htm Edgar Link pending
cytk-ex1047_585.htm Edgar Link pending
cytk-ex1048_584.htm Edgar Link pending
cytk-ex231_24.htm Edgar Link pending
cytk-ex311_23.htm Edgar Link pending
cytk-ex312_22.htm Edgar Link pending
cytk-ex313_475.htm Edgar Link pending
cytk-ex321_21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018030520471033138170.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending